Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis

Cancer

Volumn 106, Issue 9, 2006, Pages 1985-1989

  Dingli, David ^a   Schwager, Susan M ^a   Mesa, Ruben A ^a   Li, Chin Yang ^a   Dewald, Gordon W ^a   Tefferi, Ayalew ^a,b  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Chronic myeloproliferative disorders; Essential thrombocythemia; Myelofibrosis; Polycythemia vera

Indexed keywords

HEMOGLOBIN;

ADULT; ANEMIA; ARTICLE; CANCER SURVIVAL; CHROMOSOME 13Q; CHROMOSOME 20Q; CHROMOSOME ABERRATION; CYTOGENETICS; FEMALE; HEMOGLOBIN ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MULTIVARIATE ANALYSIS; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA; POLYCYTHEMIA VERA; POSTPOLYCYTHEMIC MYELOID METAPLASIA; POSTTHROMBOCYTHEMIC MYELOID METAPLASIA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SECONDARY MYELOFIBROSIS; THROMBOCYTHEMIA; THROMBOCYTOPENIA; UNITED STATES;

ADULT; AGED; CHROMOSOME ABERRATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELOFIBROSIS; POLYCYTHEMIA VERA; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 30844463437     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21868     Document Type: Article

References (23)

1. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342:1255-1265.
2. Barosi G, Ambrosetti A, Finelli C, et al. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol. 1999;104:730-737.
3. Passamonti F, Malabarba L, Orlandi E, et al. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica. 2003;88:13-18.
4. Cervantes F, Alvarez-Larran A, Talarn C, Gomez M, Montserrat E. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol. 2002;118:786-790.
5. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88:1013-1018.
6. Cervantes F, Pereira A, Esteve J, et al. Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis. Br J Haematol. 1997;97:635-640.
7. Cervantes F, Pereira A, Esteve J, et al. Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis. Br J Haematol. 1997;97:635-640.
8. Rupoli S, Da Lio L, Sisti S, et al. Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival. Ann Hematol. 1994;68:205-212.
9. Okamura T, Kinukawa N, Niho Y, Mizoguchi H. Primary chronic myelofibrosis: clinical and prognostic evaluation in 336 Japanese patients. Int J Hematol. 2001;73:194-198.
10. Cervantes F, Barosi G, Demory JL, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol. 1998;102:684-690.
11. Reilly JT, Snowden JA, Spearing RL, et al. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol. 1997;98:96-102.
12. Dingli D, Schwager SM, Mesa RA, Li C-Y, Tefferi A. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system. Cancer. 2006;106:623-630.
13. Visani G, Finelli C, Castelli U, et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol. 1990;75:4-9.
14. Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol. 2001;113:763-771.
15. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumors: tumors of the hematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001.
16. Yoon SY, Li CY, Mesa RA, Tefferi A. Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 1999;106:682-688.
17. Tefferi A, Dingli D, Li C-Y, Dewald GW. Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia. Cancer. 2005;104:1656-1660.
18. Demory JL, Dupriez B, Fenaux P, et al. Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: a report on 47 cases. Blood. 1988;72:855-859.
19. Tefferi A, Meyer RG, Wyatt WA, Dewald GW. Comparison of peripheral blood interphase cytogenetics with bone marrow karyotype analysis in myelofibrosis with myeloid metaplasia. Br J Haematol. 2001;115:316-319.
20. Najean Y, Mugnier P, Dresch C, Rain JD. Polycythaemia vera in young people: an analysis of 58 cases diagnosed before 40 years. Br J Haematol. 1987;67:285-291.
21. Najean Y, Dresch C, Rain JD. The very-long-term course of polycythaemia: a complement to the previously published data of the Polycythaemia Vera Study Group. Br J Haematol. 1994;86:233-235.
22. Messinezy M, Pearson TC, Prochazka A, Wetherley-Mein G. Treatment of primary proliferative polycythaemia by venesection and low dose busulphan: retrospective study from one centre. Br J Haematol. 1985;61:657-666.
23. Thiele J, Kvasnicka HM, Zankovich R, Diehl V. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis. Haematologica. 2000;85:1126-1134.